- Home
- NKSH vs IPHA Comparison
NKSH vs IPHA Comparison
Compare NKSH & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- IPHA
- Stock Information
- Founded
- NKSH 1891
- IPHA 1999
- Country
- NKSH United States
- IPHA France
- Employees
- NKSH N/A
- IPHA N/A
- Industry
- NKSH Major Banks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- IPHA Health Care
- Exchange
- NKSH Nasdaq
- IPHA Nasdaq
- Market Cap
- NKSH 180.8M
- IPHA 148.3M
- IPO Year
- NKSH N/A
- IPHA 2019
- Fundamental
- Price
- NKSH $29.14
- IPHA $1.69
- Analyst Decision
- NKSH Strong Buy
- IPHA Strong Buy
- Analyst Count
- NKSH 1
- IPHA 1
- Target Price
- NKSH $38.00
- IPHA $11.50
- AVG Volume (30 Days)
- NKSH 13.9K
- IPHA 59.0K
- Earning Date
- NKSH 10-24-2024
- IPHA 09-12-2024
- Dividend Yield
- NKSH 5.28%
- IPHA N/A
- EPS Growth
- NKSH N/A
- IPHA N/A
- EPS
- NKSH 1.44
- IPHA N/A
- Revenue
- NKSH $43,450,000.00
- IPHA $36,202,722.00
- Revenue This Year
- NKSH N/A
- IPHA N/A
- Revenue Next Year
- NKSH $19.72
- IPHA $101.65
- P/E Ratio
- NKSH $19.81
- IPHA N/A
- Revenue Growth
- NKSH N/A
- IPHA N/A
- 52 Week Low
- NKSH $26.00
- IPHA $1.29
- 52 Week High
- NKSH $35.00
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- NKSH 51.10
- IPHA 42.95
- Support Level
- NKSH $26.00
- IPHA $1.60
- Resistance Level
- NKSH $29.66
- IPHA $1.87
- Average True Range (ATR)
- NKSH 0.94
- IPHA 0.13
- MACD
- NKSH 0.18
- IPHA -0.04
- Stochastic Oscillator
- NKSH 85.79
- IPHA 16.67
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.